Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP

SCHAUMBURG, Ill., July 16 IL-Sagent-Pharmaceut


SCHAUMBURG, Ill., July 16 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a
privately-held specialty pharmaceutical company, today announced that it has
launched both ceftriaxone for injection, USP, and cefuroxime for injection,
USP, two broad spectrum antibiotics for parenteral administration used to
treat bacterial infections.  Sagent's ceftriaxone for injection will be
available to the U.S. market in 250 mg and 500 mg single dose vials, as well
as 1g and 2g single dose vials; cefuroxime for injection will be available in
750 mg and 1.5g single dose vials and in 7.5g pharmacy bulk package vials.
According to IMS data, combined 2007 sales for the two antibiotics were $156
million.


"We are excited to introduce these two broad-spectrum antibiotics,
incorporating important features unique to Sagent, including enhanced labeling
designed to enable rapid and accurate product identification," said Jeffrey M.
Yordon, Sagent's chief executive officer, founder, and chairman of the board.
"Importantly, this marks our fifth and sixth product launches in the past
eight months, in line with our objective of rapidly introducing safe, high-
quality products from our pipeline of over 200 products.  Sagent is committed
to bringing injectables excellence to healthcare providers and patients."



About Ceftriaxone


Ceftriaxone for injection, USP, is a broad spectrum cephalosporin
antibiotic used to treat a variety of infections and is the generic equivalent
of Roche's Rocephin(R) (ceftriaxone for injection).  Ceftriaxone for
injection, USP, is indicated for infections of the lower respiratory tract,
urinary tract, skin and skin-structure, intra-abdomen, and bones and joints,
as well as acute otitis media, uncomplicated gonorrhea, pelvic inflammatory
disease, bacterial septicemia and meningitis.  Ceftriaxone may also reduce the
incidence of postoperative infections is used as a surgical prophylaxis
preoperatively.


The most common adverse effects may include nausea, vomiting, stomach
pain, headache, dizziness, sweating and vaginal itching or discharge.  Less
common adverse effects include watery or bloody diarrhea; fever or chills;
skin rash; bruising; severe tingling; numbness; pain; muscle weakness;
injection site pain, swelling or irritation; heartburn; bloating; and severe
upper stomach pain.



About Cefuroxime


Cefuroxime for injection, USP, is a semisynthetic broad spectrum
antibiotic agent for parenteral administration used to treat a variety of
infections and is the generic equivalent of GlaxoSmithKline's ZINACEF(R)
(cefuroxime for injection).  Cefuroxime belongs to the cephalosporin family of
drugs.  Cefuroxime for injection, USP, is indicated for infections of the
lower respiratory tract, urinary tract, skin and skin-structure, and bones and
joints, as well as septicemia, meningitis, gonorrhea.  In certain cases of
confirmed or suspected gram-positive or gram-negative sepsis or in patients
with other serious infections in which the causative organism has not been
identified, cefuroxime may be used concomitantly with an aminoglycoside.
Cefuroxime may be used prophylactically to prevent the growth of susceptible
disease-causing bacteria and thereby may reduce the incidence of certain
postoperative infections in patients undergoing surgical procedures that are
classified as clean-contaminated or potentially contaminated procedures.


The most common adverse effects may include pain, swelling or redness at
the injection site. Less common adverse effects include severe allergic
reactions; black or bloody stools; decreased urination; fever, chills, or sore
throat; hearing loss; seizures; severe diarrhea, nausea, or vomiting; stomach
pain or cramps; unusual bruising or bleeding; vaginal irritation or discharge;
vein swelling at the injection site; yellowing of the skin or eyes.



About Sagent Pharmaceuticals, Inc.


Sagent Pharmaceuticals, founded in 2006, is a privately held specialty
pharmaceutical company focused on developing, manufacturing, sourcing and
marketing pharmaceutical products, with a specific emphasis on injectable
products.  Sagent has created a unique, global network of resources, comprised
of rapid development capabilities, sophisticated manufacturing and innovative
drug-delivery technologies, quickly yielding an extensive portfolio of
pharmaceutical products that fulfills the evolving needs of patients.  Sagent
currently has more than 200 products in development.


To Discover Injectables Excellence(TM) and learn more about Sagent, please
visit http://www.SagentPharma.com.



SOURCE  Sagent Pharmaceuticals, Inc.